Please assess the completion status of the following clinical trial:

Trial Title: Chemoradiation in Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have newly diagnosed computated tomography (CT) and endoscopic ultrasound(EUS) stage Tx-4, N0-1, M0 adenocarcinoma of pancreas according to the American Joint Committee on Cancer (AJCC) staging system. The following cell types will NOT be eligible: adenosquamous carcinoma, ampullary carcinoma, carcinoid tumor, cystadenocarcinoma, cystadenoma, distal common bile duct carcinoma, duodenal carcinoma, or islet cell carcinoma~* Treatment must begin within 60 days of diagnosis~* Must have locally advanced inoperable pancreatic cancer with no metastatic spread as determined by a baseline diagnostic CT scan of the chest, endoscopic ultrasound and CT scan with intravenous (IV) contrast (or MRI) of abdomen/pelvis, within 30 days prior to registration.~* No prior systemic chemotherapy or radiation therapy for pancreatic cancer~* Documented Eastern Cooperative Oncology Group (ECOG/Zubrod) performance status 0-1 within 14 days prior to registration~* Adequate hematologic, renal and hepatic function as defined by the following laboratory values (completed within 14 days prior to registration)~  * white blood cell (WBC) \> 3,000 mm3~ * absolute neutrophil count (ANC) \> 1,500 mm3~ * platelet count ≥ 100,000 mm3~ * hemoglobin \> 9.5 g/dl~ * serum creatinine \< 1.5 times institutional upper limit of normal (ULN)~ * total bilirubin ≤ 3 mg/dl~ * AST (SGOT) \< 4.0 times institutional ULN~ * ALT (SGPT) \< 4.0 times institutional ULN~ * alkaline phosphatase \< 2.0 times institutional ULN~* Age ≥ 18 years~* Life expectancy ≥ 12 weeks~* Patient (male or female) of reproductive potential are required to use a medically acceptable contraception during treatment and for 3 months after the last dose of chemotherapy.~* Not pregnant or breastfeeding since the drugs used in this study are Pregnancy Category D: Clear evidence of risk in pregnancy. A negative pregnancy test is required within 7 days of registration if pre- or perimenopausal (i.e., last menstrual period within one year of registration)~* If patient has a previous diagnosis of cancer, all of the following criteria must be met and documented in the patient's medical record:~  * Patient has undergone potentially curative therapy for all prior malignancies.~ * No evidence of prior malignancies for at least 5 years (except for successfully treated cervical carcinoma in situ, carcinoma in situ of the breast, or nonmelanoma skin cancer.~ * No evidence of recurrence of any prior malignancy.~* Patient who is receiving chronic immunotherapy (e.g. prednisone or methotrexate) for collagen vascular disease or other chronic immunologic abnormality are not eligible.~* Not requiring one or more of the contraindicated medications~* Patient must be able to understand the potential risks and benefits associated with this study. Patient able to give informed consent and would likely to comply with the study parameters.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pancreatic Adenocarcinoma Patients (Type: EXPERIMENTAL): Pancreatic Adenocarcinoma Patients treated with chemotherapy regimen and radiation (and or surgery).

Based on this trial design, predict the completion outcome and termination type (if applicable).